MeSH term
Frequency | Condition_Probility | Adolescent | 7 | 0.0 |
Adult | 22 | 0.0 |
Aged | 24 | 0.0 |
Estrogen Receptor alpha | 18 | 7.0 |
Female | 43 | 0.0 |
Gene Frequency | 11 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
Genotype | 21 | 0.0 |
Humans | 57 | 0.0 |
Male | 34 | 0.0 |
Middle Aged | 30 | 0.0 |
Multiple Sclerosis/*genetics | 2 | 2.0 |
*Polymorphism, Genetic | 11 | 0.0 |
Receptors, Estrogen/*genetics | 23 | 27.0 |
Polymorphism, Genetic | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 44 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Estrogen Receptor alpha/*genetics | 2 | 100.0 |
Introns | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 6 | 1.0 |
Risk Factors | 8 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Comparative Study | 4 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
*DNA Methylation | 12 | 1.0 |
DNA Primers | 4 | 0.0 |
Genetic Markers | 4 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Logistic Models | 2 | 0.0 |
Odds Ratio | 2 | 0.0 |
Alleles | 15 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
Estrogen Receptor beta | 3 | 3.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Heterozygote | 3 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Haplotypes | 6 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Animals | 4 | 0.0 |
Breast Neoplasms/*genetics | 5 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cohort Studies | 3 | 0.0 |
*Dinucleotide Repeats | 2 | 5.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Base Sequence | 6 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Case-Control Studies | 9 | 0.0 |
CpG Islands/*genetics | 3 | 3.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
CpG Islands/genetics | 2 | 1.0 |
Child | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Survival Rate | 2 | 0.0 |
Bone Density | 2 | 1.0 |
*Hormone Replacement Therapy | 2 | 5.0 |
Postmenopause | 2 | 1.0 |
Regression Analysis | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Lod Score | 2 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Aromatase/genetics | 2 | 14.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Bone Density/*genetics | 4 | 3.0 |
Reproducibility of Results | 2 | 0.0 |
Lumbar Vertebrae | 2 | 10.0 |
*Postmenopause | 2 | 3.0 |
Japan | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
